Home » Stocks » XGN

Exagen Inc. (XGN)

Stock Price: $16.06 USD 0.03 (0.19%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 203.19M
Revenue (ttm) 39.52M
Net Income (ttm) -16.64M
Shares Out 12.64M
EPS (ttm) -72.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $16.06
Previous Close $16.03
Change ($) 0.03
Change (%) 0.19%
Day's Open 16.20
Day's Range 15.83 - 16.75
Day's Volume 38,965
52-Week Range 10.56 - 23.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

GlobeNewsWire - 2 weeks ago

Record Testing Revenue, Adopters and AVISE CTD® Volumes

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

Zacks Investment Research - 2 weeks ago

Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Investment Research - 1 month ago

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Other stocks mentioned: TMDX, MYO
GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoim...

Seeking Alpha - 2 months ago

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Exagen (NASDAQ:XGN) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 83.65% year over year to ($0.34), which beat...

GlobeNewsWire - 2 months ago

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today anno...

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today anno...

GlobeNewsWire - 3 months ago

SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic aut...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is prou...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today a...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today a...

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announce...

GlobeNewsWire - 5 months ago

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today an...

Seeking Alpha - 5 months ago

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63%

GlobeNewsWire - 5 months ago

AVISE Tests Now Available to 6 Million Humana Military Beneficiaries AVISE Tests Now Available to 6 Million Humana Military Beneficiaries

GlobeNewsWire - 6 months ago

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today an...

Zacks Investment Research - 6 months ago

Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today an...

GlobeNewsWire - 7 months ago

SAN DIEGO, June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announce...

Seeking Alpha - 8 months ago

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today a...

GlobeNewsWire - 10 months ago

SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...

GlobeNewsWire - 10 months ago

SAN DIEGO, CA, March 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...

About XGN

Exagen develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Sep 19, 2019
CEO
Fortunato Rocca
Employees
153
Stock Exchange
NASDAQ
Ticker Symbol
XGN
Full Company Profile

Financial Performance

In 2019, Exagen's revenue was $40.39 million, an increase of 24.50% compared to the previous year's $32.44 million. Losses were -$12.04 million, 50.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Exagen stock is "Strong Buy." The 12-month stock price forecast is 24.25, which is an increase of 51.00% from the latest price.

Price Target
$24.25
(51.00% upside)
Analyst Consensus: Strong Buy